Factor VIII pharmacokinetics: intermittent infusion versus continuous infusion

Area of Science:

• Hematology
• Pharmacology

Background:

• Advancements in recombinant DNA technology have increased the purity of clotting factor concentrates.
• Evaluating the in vivo behavior of these novel products in hemophiliacs necessitates standardized techniques.

Purpose of the Study:

• To apply pharmacokinetic principles for evaluating clotting factor concentrates.
• To define kinetic parameters for single- and repeated-dose studies of these concentrates.

Main Methods:

• Pharmacokinetic principles were applied to study clotting factor concentrates.
• Comparison of different treatment schedules involving repeated bolus infusions.
• Analysis of continuous infusion delivery of factor concentrate.

Main Results:

• Dose reduction at steady state is inversely proportional to the time interval between administrations.
• Continuous infusion results in maximum dose-sparing as the time interval is zero.
• Continuous infusion demonstrates significant advantages for hemophiliacs undergoing surgical procedures.

Conclusions:

• Pharmacokinetic evaluation is crucial for new clotting factor concentrates.
• Continuous infusion represents an optimal strategy for maximizing dose efficiency in hemophilia treatment.
• The findings support the use of continuous infusion for hemophiliacs, particularly in surgical contexts.